Dr. Atkins on Sequencing of Immunotherapy Combination Regimens for RCC

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

Dr. Rini on Sequencing of Immunotherapy Combinations in RCCПодробнее

Dr. Chowdhury on Sequencing of Immunotherapy Regimens for RCCПодробнее

Dr. Atkins on Excitement With Atezolizumab and Bevacizumab in RCCПодробнее

Atkins: Pembrolizumab, Ipilimumab for Melanoma, RCCПодробнее

Michael Atkins, MD, regarding the KEYNOTE 426 Phase III trial in metastatic renal cell carcinomaПодробнее

Emerging Immunotherapy Combinations in Kidney CancerПодробнее

Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCCПодробнее

The agents at the forefront of kidney cancer treatmentПодробнее

Dr. Gupta Discusses Combination Immunotherapy in RCCПодробнее

RCC: Following Patients on Immunotherapy Vs TKI TherapyПодробнее

Recent Data in the Adjuvant Setting of RCCПодробнее

Clinical trials in kidney cancer to look out forПодробнее

Next steps for combination immunotherapies for RCCПодробнее

Combination pembrolizumab and reduced-dose ipilimumab: how low can you go?Подробнее

Dr. Choueiri on Trials Investigating Combination Regimens for RCCПодробнее

Navigating Evolving Standards of Care in RCC: Novel Targeted and Immunotherapy OptionsПодробнее

Sequencing Metastatic Renal Cell Carcinoma TreatmentsПодробнее

Sequencing Therapies After Progression of RCCПодробнее